Sberro-Soussan Rebecca, Zuberl Julien, Suberbielle-Boissel Caroline, Legendre Christophe
Service de Transplantation Rénale, Hôpital Necker, Paris, France.
Clin Transpl. 2010:409-14.
In a previous study we evaluated the in vivo efficacy of one cycle of Bortezomib (1.3 mg/m2 x 4 doses), used as the sole desensitization therapy, in four renal transplant recipients experiencing sub-acute antibody mediated rejection with persisting DSA. Bortezomib treatment did not significantly decrease DSA MFI within the 270-day posttreatment period in any patient. Here we reevaluate the patients' outcomes and bortezomib efficacy after one year post-treatment. The DSA levels remained stable or increased. In conclusion, one cycle of bortezomib alone does not decrease DSA levels in sensitized kidney transplant recipients.
在之前的一项研究中，我们评估了硼替佐米（1.3 mg/m²，共4剂）单周期作为唯一脱敏疗法，对4例经历亚急性抗体介导排斥反应且持续存在供者特异性抗体（DSA）的肾移植受者的体内疗效。在任何患者中，硼替佐米治疗在治疗后270天内均未显著降低DSA平均荧光强度（MFI）。在此，我们重新评估治疗一年后患者的结局及硼替佐米疗效。DSA水平保持稳定或升高。总之，单周期硼替佐米并不能降低致敏肾移植受者的DSA水平。
